LEADARTIS, THE LEADING IMMUNO-ONCOLOGY COMPANY IN SPAIN, OPENS A €1 MILLION ROUND TOGETHER WITH INVEREADY, SODENA AND CDTI INNVIERTE FOR THE DEVELOPMENT OF ITS FIRST PRODUCT IN ADVANCED CANCERS

11-09-2020

LEADARTIS, a company dedicated to the development of IMMUNO-ONCOLOGICAL medicines based on its own technology (Trimerbody®), opens a financing round of € 1M through the investment platform specialized in biomedicine, Capital Cell. The goal is to continue its research for its first third generation immuno-oncological agent against advanced cancers of the lung, breast and colon. Specifically, the forecast is to finance Phase I studies of its bispecific Trimerbody in patients with advanced or resistant cancers without a therapeutic option. Currently, € 4M have already been achieved, 80% of the investment of the planned amount, through three relevant venture capital funds, Inveready acting as leading investor, SODENA and CDTI innvierte.

If the results are as expected, the company will be able to develop additional products against any type of cancer. A problem that, in many cases, does not have efficacious treatments and that affects many millions of people around the world.

"Trimerbody has proven to be an especially safe product and preclinical studies led us to expect good results in the clinical trial," stated Dr. Marta Compte MD, PhD, Director of Research and Development at LEADARTIS.

"We hope that our work contributes to improving the lives of many people, especially cancer patients without a therapeutic alternative," says Dr. Juan J. Pérez Villar, CEO of LEADARTIS with extensive experience in the United States in the development of anti-cancer drugs. Other international companies developing cancer treatments, without the potential of our technology, already have capitalization values ​​of up to € 1000M.

LEADARTIS started its project in 2014 and has the support of important investment groups such as venture capital entities including Inveready (http://inveready.com/ ) and Sodena (Sociedad de Desarrollo de Navarra, www.sodena.com ).

Latest News

Leadartis presenting at the AseBio Investor Day 2020
17-09-2020

Leadartis will be presenting its business proposal at the AseBio Investor Day (...

LEADARTIS, THE LEADING IMMUNO-ONCOLOGY COMPANY IN SPAIN, OPENS A €1 MILLION ROUND TOGETHER WITH INVEREADY, SODENA AND CDTI INNVIERTE FOR THE DEVELOPMENT OF ITS FIRST PRODUCT IN ADVANCED CANCERS
11-09-2020

LEADARTIS, a company dedicated to the development of IMMUNO-ONCOLOGICAL medicines based on its...

Investigadores crean molécula eficaz ante el progreso de células tumorales
15-11-2018

LA VANGUARDIA

Madrid, 15 nov (EFE).- Un grupo de investigadores del Hospital 12 de...